ProteoTech Inc.
www.proteotech.com
Latest From ProteoTech Inc.
Execs On The Move, February 2015
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
Deals Shaping the Medical Industry (12/2010)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions
Building the New Generation of Drugs in Neurodegeneration
Neurodegenerative diseases have emerged as one of the toughest and potentially most attractive frontiers in specialty drug development. Companies interested in the NDD space have the option of pursuing several strategies: disease-modifying therapies, symptom management therapies, or a hybrid approach, in which symptom-modifying drugs provide near-term revenues but also have longer-term potential for disease modification. Given the extraordinary difficulty associated with producing a successful disease-modifying new therapy, drugs aimed at treating symptoms are likely to dominate the NDD space for years. Licensors are rewarding developers with promising symptom modification programs with attractive deals.
ProteoTech Inc.
While researches continue to debate the molecular causes of Alzheimer's disease, they do agree that pathological deposits of the beta-amyloid protein are responsible for some of the disease's destructive effects. Researchers at the University of Washington believe they have found a novel aproach that interferes with the harmful formation of amyloid deposits, and have founded ProteoTech Inc. to develop proteoglycan technologies.
Company Information
- Industry
-
Biotechnology
- Large Molecule
-
Pharmaceuticals
-
Drug Delivery
- Nasal
-
Drug Delivery
- Therapeutic Areas
- Metabolic Disorders
- Neurology, Nervous System
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- ProteoTech Inc.
- Senior Management
-
Roger S Flugel, PhD, CEO
Dennis L McCurley, COO & CFO
Alan D Snow, PhD, Pres. & CSO - Contact Info
-
ProteoTech Inc.
Phone: (425) 823-0400
12040 115th Ave., NE
Kirkland, WA 98034
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ProteoTech Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice